SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company focused on innovative treatments for allergic reactions, announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for EURneffy, an adrenaline nasal spray, for the emergency treatment of allergic reactions (anaphylaxis) in adults and children over 30 kg. This marks the first and only needle-free emergency treatment available in the U.K. for severe allergies, offering a new delivery method for adrenaline. The approval is a significant milestone in ARS Pharma's collaboration with ALK-Abelló A/S, who will market EURneffy in the U.K., with expected availability in late Q3 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.